LONG-TERM FOLLOW-UP RESULTS OF PATIENTS WITH STAGE IC-IV OVARIAN-CANCER TREATED WITH CISPLATIN, EPIRUBICIN AND IFOSFAMIDE CHEMOTHERAPY
- Authors:
- Published online on: September 1, 1995 https://doi.org/10.3892/or.2.5.731
- Pages: 731-736
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Sixty-three patients with stage Ic-IV ovarian cancer received cisplatin, epirubicin and ifosfamide chemotherapy following a staging surgery between 1985 and 1992. The optimal surgery (without macroscopic residual was completed in 44 patients including 12 stage III cases. A 5-year survival of 97.5% was obtained for the optimal cases; whereas that for suboptimal cases was only 24.0%. From the results, the regimen proved to be a promising adjuvant therapy for ovarian cancer after optimal surgery; moreover a need for a drastic amelioration of strategy is emphasized in the treatment of advanced ovarian cancer with extensive metastases.